- Home
- TSHA vs KSS Comparison
TSHA vs KSS Comparison
Compare TSHA & KSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | KSS |
|---|---|---|
| Founded | 2019 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TSHA | KSS |
|---|---|---|
| Price | $4.60 | $13.64 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 15 |
| Target Price | $11.11 | ★ $15.31 |
| AVG Volume (30 Days) | 2.8M | ★ 4.6M |
| Earning Date | 05-14-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 3.88% |
| EPS Growth | 5.56 | ★ 142.86 |
| EPS | N/A | ★ 2.38 |
| Revenue | ★ $9,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,228.40 | $0.09 |
| P/E Ratio | ★ N/A | $5.41 |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $1.13 | $6.04 |
| 52 Week High | $6.02 | $25.22 |
Technical Indicators
Market Signals| Indicator | TSHA | KSS |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 48.56 |
| Support Level | $4.33 | $12.07 |
| Resistance Level | $4.72 | $16.95 |
| Average True Range (ATR) | 0.28 | 0.60 |
| MACD | 0.04 | 0.28 |
| Stochastic Oscillator | 70.00 | 86.93 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About KSS Kohl's Corporation
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.